Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 13 | 2023 | 1324 | 2.620 |
Why?
|
| HIV Infections | 27 | 2025 | 5097 | 2.300 |
Why?
|
| Pre-Exposure Prophylaxis | 5 | 2023 | 196 | 1.650 |
Why?
|
| Cost-Benefit Analysis | 14 | 2025 | 253 | 1.410 |
Why?
|
| Sex Workers | 3 | 2022 | 116 | 1.020 |
Why?
|
| Sexual and Gender Minorities | 2 | 2022 | 29 | 0.960 |
Why?
|
| Anti-Retroviral Agents | 6 | 2023 | 551 | 0.850 |
Why?
|
| Epidemics | 4 | 2024 | 65 | 0.790 |
Why?
|
| Humans | 31 | 2025 | 14537 | 0.730 |
Why?
|
| South Africa | 25 | 2025 | 7596 | 0.720 |
Why?
|
| Tenofovir | 2 | 2022 | 171 | 0.680 |
Why?
|
| Data Accuracy | 1 | 2019 | 9 | 0.660 |
Why?
|
| Registries | 1 | 2019 | 91 | 0.620 |
Why?
|
| Sexual Partners | 1 | 2020 | 215 | 0.610 |
Why?
|
| Female | 17 | 2025 | 9103 | 0.610 |
Why?
|
| Male | 15 | 2025 | 6754 | 0.600 |
Why?
|
| Tuberculosis | 2 | 2024 | 543 | 0.600 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 226 | 0.530 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 33 | 0.530 |
Why?
|
| Adolescent | 8 | 2025 | 2985 | 0.450 |
Why?
|
| Models, Theoretical | 7 | 2024 | 80 | 0.440 |
Why?
|
| Adult | 12 | 2025 | 5913 | 0.440 |
Why?
|
| Emtricitabine | 3 | 2022 | 78 | 0.430 |
Why?
|
| Retrospective Studies | 5 | 2024 | 799 | 0.410 |
Why?
|
| Pyridones | 2 | 2023 | 100 | 0.380 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 52 | 0.360 |
Why?
|
| Young Adult | 8 | 2025 | 2498 | 0.350 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 187 | 0.350 |
Why?
|
| Pregnancy | 5 | 2024 | 1862 | 0.330 |
Why?
|
| Zambia | 3 | 2023 | 115 | 0.290 |
Why?
|
| Mass Screening | 2 | 2021 | 245 | 0.290 |
Why?
|
| Hypertension | 2 | 2025 | 419 | 0.280 |
Why?
|
| Diketopiperazines | 1 | 2023 | 6 | 0.220 |
Why?
|
| Circumcision, Male | 2 | 2022 | 99 | 0.220 |
Why?
|
| Immunization Programs | 1 | 2024 | 81 | 0.210 |
Why?
|
| Antihypertensive Agents | 2 | 2025 | 64 | 0.210 |
Why?
|
| Electronic Health Records | 1 | 2022 | 10 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2022 | 7 | 0.200 |
Why?
|
| Adenine | 1 | 2022 | 91 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2023 | 967 | 0.180 |
Why?
|
| Piperazines | 1 | 2021 | 82 | 0.180 |
Why?
|
| Oxazines | 1 | 2021 | 81 | 0.180 |
Why?
|
| Reproductive Health | 1 | 2021 | 51 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 85 | 0.180 |
Why?
|
| Unsafe Sex | 1 | 2021 | 46 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2019 | 472 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 104 | 0.160 |
Why?
|
| Middle Aged | 4 | 2025 | 3601 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2020 | 472 | 0.150 |
Why?
|
| Rifampin | 1 | 2019 | 197 | 0.150 |
Why?
|
| Financing, Personal | 1 | 2017 | 12 | 0.140 |
Why?
|
| Program Development | 1 | 2017 | 32 | 0.130 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 115 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 74 | 0.130 |
Why?
|
| Risk Factors | 2 | 2018 | 1475 | 0.130 |
Why?
|
| Health Promotion | 1 | 2017 | 109 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 468 | 0.120 |
Why?
|
| Incidence | 3 | 2023 | 685 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2017 | 889 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2018 | 529 | 0.110 |
Why?
|
| Prevalence | 3 | 2023 | 1192 | 0.100 |
Why?
|
| Child | 3 | 2023 | 2242 | 0.100 |
Why?
|
| Aged | 1 | 2017 | 1740 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 239 | 0.070 |
Why?
|
| Infant | 2 | 2023 | 2244 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 34 | 0.060 |
Why?
|
| Forecasting | 1 | 2023 | 20 | 0.050 |
Why?
|
| Drug Costs | 1 | 2023 | 18 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 132 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 120 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2022 | 54 | 0.050 |
Why?
|
| Malawi | 1 | 2022 | 87 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 179 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 125 | 0.050 |
Why?
|
| Vaccination | 1 | 2024 | 365 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 244 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 5 | 0.050 |
Why?
|
| Hospitalization | 1 | 2024 | 418 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 31 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2021 | 35 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.040 |
Why?
|
| Patient Care | 1 | 2019 | 10 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 15 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 42 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 48 | 0.040 |
Why?
|
| Budgets | 1 | 2017 | 12 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2018 | 151 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 507 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 1479 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 280 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1748 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 1160 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 265 | 0.030 |
Why?
|